Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by EULAV Asset Management

EULAV Asset Management lessened its stake in shares of Exact Sciences Co. (NASDAQ:EXAS) by 6.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 285,000 shares of the medical research company’s stock after selling 20,000 shares during the quarter. EULAV Asset Management owned about 0.15% of Exact Sciences worth $16,014,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Huntington National Bank boosted its stake in Exact Sciences by 838.1% in the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 352 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in shares of Exact Sciences in the 3rd quarter valued at about $34,000. Capital Performance Advisors LLP acquired a new stake in shares of Exact Sciences in the 3rd quarter valued at about $35,000. Modus Advisors LLC purchased a new position in Exact Sciences during the 4th quarter worth approximately $43,000. Finally, Vestor Capital LLC acquired a new position in Exact Sciences during the third quarter worth approximately $46,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Insiders Place Their Bets

In other Exact Sciences news, CEO Kevin T. Conroy purchased 19,500 shares of Exact Sciences stock in a transaction on Wednesday, November 13th. The shares were bought at an average price of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,074,191 shares of the company’s stock, valued at approximately $55,159,707.85. This trade represents a 1.85 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.36% of the stock is owned by company insiders.

Exact Sciences Stock Down 1.4 %

EXAS stock opened at $53.53 on Friday. Exact Sciences Co. has a 52 week low of $40.62 and a 52 week high of $79.62. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. The company has a market cap of $9.91 billion, a P/E ratio of -45.75 and a beta of 1.24. The company’s 50-day moving average price is $57.31 and its 200 day moving average price is $59.97.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The firm had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The business’s quarterly revenue was up 12.8% on a year-over-year basis. On average, research analysts expect that Exact Sciences Co. will post -1.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

EXAS has been the topic of a number of research reports. Canaccord Genuity Group lowered their target price on shares of Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. The Goldman Sachs Group lowered their price objective on shares of Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Bank of America reduced their target price on shares of Exact Sciences from $75.00 to $72.00 and set a “buy” rating for the company in a report on Friday, December 13th. Citigroup lowered their price target on Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Finally, Evercore ISI reduced their price objective on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Exact Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $72.76.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.